Salts and solid state forms of Valbenazine, including Valbenazine ditosylate, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof. ##STR00001##
wherein R.sub.1 is —C(═O)O-alkyl, carbonate ester, or —C(═O)-alkyl, ester, or —C(═O)N-alkyl, carbamate ester and wherein R.sub.2 is —CH.sub.3 or —CD.sub.3. The alkyl ester can contain saturated or unsaturated C.sub.12 to C.sub.26 alkyl carbon. The alkyl carbon chain can have either a straight, branched, noncyclic, cyclic, unsubstituted or substituted structure.

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof. ##STR00001##
wherein R.sub.1 is —C(═O)O-alkyl, carbonate ester, or —C(═O)-alkyl, ester, or —C(═O)N-alkyl, carbamate ester and wherein R.sub.2 is —CH.sub.3 or —CD.sub.3. The alkyl ester can contain saturated or unsaturated C.sub.12 to C.sub.26 alkyl carbon. The alkyl carbon chain can have either a straight, branched, noncyclic, cyclic, unsubstituted or substituted structure.

The present disclosure provides a series of dihydroisoquinoline compounds or a pharmaceutically acceptable salt, ester, isomer, solvate, hydrate, prodrug, or isotopically labeled compounds thereof, having the structure of general formula I: (I). The compounds have an extremely strong activity for inhibiting Hepatitis B surface antigen and has an extremely strong activity for inhibiting Hepatitis B virus DNA. In addition, the compounds feature high bioavailability and can exhibit efficacy with a low dosage, which reduces the potential toxicity of the compounds.

##STR00001##

Embodiments described herein are directed to employing an aggregation of participant sensor coverage areas to determine if there are missing coverage areas or unwanted overlapping coverage areas. If there are missing coverage areas, then at least one participant is instructed to modify its sensor coverage area to at least partially cover the missing coverage area. Conversely, if at least one participant has a sensor that is providing unwanted overlap of other sensor coverage areas, then that participant may be instructed to stop using that sensor, utilize that sensor for other data transmission purposes, or modify the coverage area to be non- or less-overlapping.

Embodiments described herein are directed to employing an aggregation of participant sensor coverage areas to determine if there are missing coverage areas or unwanted overlapping coverage areas. If there are missing coverage areas, then at least one participant is instructed to modify its sensor coverage area to at least partially cover the missing coverage area. Conversely, if at least one participant has a sensor that is providing unwanted overlap of other sensor coverage areas, then that participant may be instructed to stop using that sensor, utilize that sensor for other data transmission purposes, or modify the coverage area to be non- or less-overlapping.

The invention provides (+)-α-dihydrotetrabenazine succinate salt. Also provided are (+)-α-dihydrotetrabenazine succinate salt for use in medicine, pharmaceutical compositions comprising (+)-α-dihydrotetrabenazine succinate salt and a pharmaceutically acceptable excipient and the uses of (+)-α-dihydrotetrabenazine succinate salt as a VMAT2 receptor antagonist and in the treatment of a movement disorder such as Tourette's syndrome. The invention further provides a method for preparing the (+)-α-dihydrotetrabenazine succinate salt.

The invention provides (+)-α-dihydrotetrabenazine succinate salt. Also provided are (+)-α-dihydrotetrabenazine succinate salt for use in medicine, pharmaceutical compositions comprising (+)-α-dihydrotetrabenazine succinate salt and a pharmaceutically acceptable excipient and the uses of (+)-α-dihydrotetrabenazine succinate salt as a VMAT2 receptor antagonist and in the treatment of a movement disorder such as Tourette's syndrome. The invention further provides a method for preparing the (+)-α-dihydrotetrabenazine succinate salt.

The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.